vs
MARCUS CORP（MCS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是MARCUS CORP的1.1倍（$219.9M vs $193.5M），MARCUS CORP同比增速更快（2.8% vs 2.0%），MARCUS CORP自由现金流更多（$26.4M vs $16.8M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 8.0%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MCS vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$193.5M
营收增速更快
MCS
高出0.8%
2.0%
自由现金流更多
MCS
多$9.6M
$16.8M
两年增速更快
MCS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 0.9% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 2.8% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSOFIX
| Q4 25 | $193.5M | $219.9M | ||
| Q3 25 | $210.2M | $205.6M | ||
| Q2 25 | $206.0M | $203.1M | ||
| Q1 25 | $148.8M | $193.6M | ||
| Q4 24 | $188.3M | $215.7M | ||
| Q3 24 | $232.7M | $196.6M | ||
| Q2 24 | $176.0M | $198.6M | ||
| Q1 24 | $138.5M | $188.6M |
净利润MCSOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $16.2M | $-22.8M | ||
| Q2 25 | $7.3M | $-14.1M | ||
| Q1 25 | $-16.8M | $-53.1M | ||
| Q4 24 | $986.0K | $-29.1M | ||
| Q3 24 | $23.3M | $-27.4M | ||
| Q2 24 | $-20.2M | $-33.4M | ||
| Q1 24 | $-11.9M | $-36.0M |
毛利率MCSOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率MCSOFIX
| Q4 25 | 0.9% | 0.2% | ||
| Q3 25 | 10.8% | -8.3% | ||
| Q2 25 | 6.3% | -7.9% | ||
| Q1 25 | -13.7% | -25.2% | ||
| Q4 24 | -1.2% | -5.3% | ||
| Q3 24 | 14.1% | -9.6% | ||
| Q2 24 | 1.3% | -12.5% | ||
| Q1 24 | -12.0% | -15.6% |
净利率MCSOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 7.7% | -11.1% | ||
| Q2 25 | 3.6% | -6.9% | ||
| Q1 25 | -11.3% | -27.4% | ||
| Q4 24 | 0.5% | -13.5% | ||
| Q3 24 | 10.0% | -13.9% | ||
| Q2 24 | -11.5% | -16.8% | ||
| Q1 24 | -8.6% | -19.1% |
每股收益（稀释后）MCSOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $82.0M |
| 总债务越低越好 | $159.0M | — |
| 股东权益账面价值 | $457.4M | $450.0M |
| 总资产 | $1.0B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资MCSOFIX
| Q4 25 | $23.4M | $82.0M | ||
| Q3 25 | $7.4M | $62.9M | ||
| Q2 25 | $14.9M | $65.6M | ||
| Q1 25 | $11.9M | $58.0M | ||
| Q4 24 | $40.8M | $83.2M | ||
| Q3 24 | $28.4M | $30.1M | ||
| Q2 24 | $32.8M | $26.4M | ||
| Q1 24 | $17.3M | $27.0M |
总债务MCSOFIX
| Q4 25 | $159.0M | — | ||
| Q3 25 | $162.0M | $157.2M | ||
| Q2 25 | $179.9M | $157.0M | ||
| Q1 25 | $198.9M | $156.9M | ||
| Q4 24 | $159.1M | $157.0M | ||
| Q3 24 | $173.1M | $118.5M | ||
| Q2 24 | $175.7M | $118.0M | ||
| Q1 24 | $169.8M | $118.2M |
股东权益MCSOFIX
| Q4 25 | $457.4M | $450.0M | ||
| Q3 25 | $454.3M | $442.5M | ||
| Q2 25 | $448.4M | $458.3M | ||
| Q1 25 | $441.8M | $458.3M | ||
| Q4 24 | $464.9M | $503.1M | ||
| Q3 24 | $462.3M | $525.9M | ||
| Q2 24 | $449.4M | $546.0M | ||
| Q1 24 | $459.3M | $570.3M |
总资产MCSOFIX
| Q4 25 | $1.0B | $850.6M | ||
| Q3 25 | $1.0B | $832.6M | ||
| Q2 25 | $1.0B | $837.2M | ||
| Q1 25 | $1.0B | $823.1M | ||
| Q4 24 | $1.0B | $893.3M | ||
| Q3 24 | $1.0B | $867.9M | ||
| Q2 24 | $1.1B | $882.0M | ||
| Q1 24 | $1.0B | $906.0M |
负债/权益比MCSOFIX
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.36× | 0.36× | ||
| Q2 25 | 0.40× | 0.34× | ||
| Q1 25 | 0.45× | 0.34× | ||
| Q4 24 | 0.34× | 0.31× | ||
| Q3 24 | 0.37× | 0.23× | ||
| Q2 24 | 0.39× | 0.22× | ||
| Q1 24 | 0.37× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 13.6% | 7.6% |
| 资本支出强度资本支出/营收 | 11.6% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $989.0K | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MCSOFIX
| Q4 25 | $48.8M | $27.7M | ||
| Q3 25 | $39.1M | $12.4M | ||
| Q2 25 | $31.6M | $11.6M | ||
| Q1 25 | $-35.3M | $-18.4M | ||
| Q4 24 | $52.6M | $23.7M | ||
| Q3 24 | $30.5M | $11.7M | ||
| Q2 24 | $36.0M | $9.0M | ||
| Q1 24 | $-15.1M | $-18.6M |
自由现金流MCSOFIX
| Q4 25 | $26.4M | $16.8M | ||
| Q3 25 | $18.2M | $2.5M | ||
| Q2 25 | $14.7M | $4.5M | ||
| Q1 25 | $-58.3M | $-25.1M | ||
| Q4 24 | $27.1M | $15.2M | ||
| Q3 24 | $12.0M | $6.3M | ||
| Q2 24 | $16.1M | $-360.0K | ||
| Q1 24 | $-30.5M | $-29.1M |
自由现金流率MCSOFIX
| Q4 25 | 13.6% | 7.6% | ||
| Q3 25 | 8.7% | 1.2% | ||
| Q2 25 | 7.1% | 2.2% | ||
| Q1 25 | -39.2% | -13.0% | ||
| Q4 24 | 14.4% | 7.0% | ||
| Q3 24 | 5.2% | 3.2% | ||
| Q2 24 | 9.2% | -0.2% | ||
| Q1 24 | -22.0% | -15.4% |
资本支出强度MCSOFIX
| Q4 25 | 11.6% | 4.9% | ||
| Q3 25 | 9.9% | 4.8% | ||
| Q2 25 | 8.2% | 3.5% | ||
| Q1 25 | 15.5% | 3.5% | ||
| Q4 24 | 13.5% | 4.0% | ||
| Q3 24 | 7.9% | 2.7% | ||
| Q2 24 | 11.3% | 4.7% | ||
| Q1 24 | 11.1% | 5.6% |
现金转化率MCSOFIX
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 4.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 53.31× | — | ||
| Q3 24 | 1.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
